Abbott Laboratories (ABT)
NYSE: ABT · IEX Real-Time Price · USD
105.24
-0.72 (-0.68%)
At close: Jul 26, 2024, 4:00 PM
100.00
-5.24 (-4.98%)
After-hours: Jul 26, 2024, 7:59 PM EDT
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $10.38B in the quarter ending June 30, 2024, with 4.00% growth. This brings the company's revenue in the last twelve months to $40.73B, up 1.24% year-over-year. In the year 2023, Abbott Laboratories had annual revenue of $40.11B, down -8.12%.
Revenue (ttm)
$40.73B
Revenue Growth
+1.24%
P/S Ratio
4.57
Revenue / Employee
$353,737
Employees
114,000
Market Cap
183.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | 31.90B | 1.33B | 4.34% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 61.40B |
| Pfizer | 55.09B |
| Sanofi | 50.96B |
| AstraZeneca | 49.13B |
| Novartis AG | 48.86B |
| Thermo Fisher | 42.49B |
| Amgen | 29.53B |
| Danaher | 21.11B |
ABT News
- 1 hour ago - Abbott must pay $95 million in premature infant formula trial, jury finds - Reuters
- 12 hours ago - Should You Pick Abbott Stock At $105 After A Solid Q2? - Forbes
- 8 days ago - Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue - Investopedia
- 8 days ago - Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views - Benzinga
- 8 days ago - Abbott plans marketing push for glucose monitors beyond diabetes - Reuters
- 8 days ago - Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product - Invezz
- 8 days ago - Abbott raises annual profit forecast as strong medical device sales power quarterly beat - Reuters
- 8 days ago - Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance - PRNewsWire